Signatera assay

DEVICE2 trials

Sponsors

Washington University School of Medicine

Conditions

Gastroesophageal AdenocarcinomaMelanomaMuscle-Invasive Bladder CarcinomaNon-small Cell Lung CancerStage II Melanoma

Phase 1

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

RecruitingNCT06529822

Washington University School of MedicineGastroesophageal Adenocarcinoma, Melanoma, Muscle-Invasive Bladder Carcinoma +1

Start: 2025-03-20End: 2034-06-30Target: 64Updated: 2026-07-17

Phase 2

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

TerminatedNCT05060003

Washington University School of MedicineStage II Melanoma

Start: 2022-11-08End: 2023-11-27Updated: 2024-02-20

Related Papers

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial

Nature Medicine2025-01-0123 citations